Phase 2RecruitingPriority 2 · High priorityNCT04496349
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Plain-language summary
This trial is testing APG-115 for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
APG-115 (DRUG): QOD, 2 weeks on, 1 week off, in repeated 21-day cycles | APG-2575 (DRUG): APG-2575 given orally each day in cycle, in repeated 21-day cycles
APG-115, APG-2575
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details